-

Nimbus Therapeutics Appoints Erin Cowhig as Chief People Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the appointment of Erin Cowhig as Chief People Officer. In this newly created role, Ms. Cowhig will oversee all aspects of Nimbus’ human resources, talent acquisition and management, and diversity and inclusion efforts.

“Our people are the reason for Nimbus’ many years of success. With Erin’s leadership as Chief People Officer we are excited to further build our high-performing team, continuing to recruit talented and diverse new Nimbi, develop and invest in our people, and foster a values-driven culture,” said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. “We’re very excited to welcome Erin to the Nimbus team and are confident that her deep experience in human resources, talent acquisition, and diversity and inclusion will contribute to driving Nimbus’ future success.”

Prior to joining Nimbus, Ms. Cowhig was Vice President, Human Resources at Vertex Pharmaceuticals, where she was responsible for HR governance, portfolio management, and organizational effectiveness as well as serving on Vertex’s HR leadership team. Ms. Cowhig was also responsible for leading Vertex’s Diversity and Inclusion strategy. Prior to Vertex, Ms. Cowhig was Senior Director and Head of Talent at Agios Pharmaceuticals, where she led talent acquisition and talent management efforts amidst the company’s transition from a research-focused organization to a late-stage development and commercial company. Ms. Cowhig holds a B.S. in human development and a Master of Industrial and Labor Relations, both from Cornell University.

“Nimbus’ community of passionate, talented people is an incredible asset, and it’s a team I feel privileged to join,” said Ms. Cowhig. “I’m excited to build upon the people-centric culture Nimbus has created to continue to make Nimbus a place of diverse, engaged, top-notch people who are empowered to do their best work and to make a difference in the lives of patients.”

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com.

Contacts

Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications
lisa@tenbridgecommunications.com

Nimbus Therapeutics


Release Summary
Nimbus Therapeutics announces the appointment of Erin Cowhig as Chief People Officer.
Release Versions

Contacts

Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications
lisa@tenbridgecommunications.com

More News From Nimbus Therapeutics

Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors

BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced that Katharine Knobil, M.D., has been appointed to the Company’s Board of Directors. Dr. Knobil is a seasoned executive with more than 20 years of experience in pharmaceutical research and product development including global clinical research, medical...

Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline

BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways. These programs, targeting the salt-inducible kinase (SIK) family and cyclic GMP-AMP synthase (cGAS), represent promising opportunities to leverage Ni...

Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications

BOSTON--(BUSINESS WIRE)--Anagenex and Nimbus Therapeutics (Nimbus) today announced they have initiated a research collaboration. Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI), will work closely with Nimbus to discover small molecule drugs for multiple challenging targets. Through this multi-target collaboration, the companies will apply Anagenex’s AI driven parallel biochemistry platform to generate billions of ex...
Back to Newsroom